back in GENR at 1.27 swing for april 26 presentation
Genaera Corporation to Present at 6th Annual Fortis Bank Biotechnology Conference
Monday April 24, 9:00 am ET
PLYMOUTH MEETING, Pa., April 24 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR - News) will present at the 6th Annual Fortis Bank Biotechnology Conference being held April 26, 2006 at the Four Seasons Hotel, Park Lane, London, UK. Jack Armstrong, President and Chief Executive Officer, will present at 9:00 AM GMT.
ADVERTISEMENT
The presentation will be an overview of the Company's development programs and will highlight recent findings, including fellow eye data, from the Company's Phase II clinical trials with EVIZON(TM) (squalamine lactate) for the treatment of wet age-related macular degeneration (AMD). In addition, the Company will present recent findings related to its anti-obesity compound, MSI-1436.
Genaera Corporation is a biopharmaceutical company committed to developing medicines to address substantial unmet medical needs in major pharmaceutical markets. The Company has four products in development for the treatment of eye, cancer and respiratory disorders. EVIZON(TM) (squalamine lactate) is Genaera's lead product in development for ophthalmic indications, specifically wet age-related macular degeneration (AMD). Genaera's other programs include: squalamine for the treatment of cancer; interleukin-9 antibody, a respiratory treatment based on the discovery of a genetic cause of asthma; and LOMUCIN(TM), a mucoregulator to treat the overproduction of mucus and secretions involved in many forms of chronic respiratory disease.
